Abstract | PURPOSE: METHODS: Three doses of each compound were evaluated under acute conditions (1, 10, and 30 µg/kg s.c.), and two doses during a chronic (4-week) infusion (3 and 10 µg/kg/h s.c.). RESULTS: CONCLUSIONS:
AP102 is a new dual SSTR2/SSTR5-specific somatostatin analog that acutely reduces growth hormone but does not cause hyperglycemia during acute or chronic administration in a healthy rat model. Further studies in diabetic animals and in humans are necessary to determine the potential utility of AP102 in the clinical setting.
|
Authors | Erika Tarasco, Petra Seebeck, Svende Pfundstein, Adrian F Daly, Philippe J Eugster, Alan G Harris, Eric Grouzmann, Thomas A Lutz, Christina N Boyle |
Journal | Endocrine
(Endocrine)
Vol. 58
Issue 1
Pg. 124-133
(Oct 2017)
ISSN: 1559-0100 [Electronic] United States |
PMID | 28822091
(Publication Type: Journal Article)
|
Chemical References |
- Hormones
- Insulin
- Receptors, Somatostatin
- Sstr2 protein, rat
- Somatostatin
- somatostatin receptor 5
- Growth Hormone
- pasireotide
- Glucose
|
Topics |
- Animals
- Glucose
(metabolism)
- Glucose Tolerance Test
- Growth
(drug effects)
- Growth Hormone
(blood)
- Hormones
(metabolism)
- Infusions, Subcutaneous
- Insulin
(blood)
- Male
- Rats
- Rats, Sprague-Dawley
- Receptors, Somatostatin
(drug effects)
- Somatostatin
(analogs & derivatives, pharmacology)
|